This is an aggregated industry headline. Read the full story at BioPharma Dive →
Scribe secures $129M in a rare gene editing IPO
The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotech companies that have gone public in 2026.
By BioPharma Dive
· Jul 24, 2026
· via BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
An FDA advisory committee has recommended that four peptide drugs that were previously restricted because of p…
The WeekFierceBiotech ↗
Sanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once t…
The WeekDrug Channels ↗
Today's guest post comes from Chip Parkinson, CEO at Gifthealth. Chip discusses how Direct-to-Patient (DTP) mo…